[{"address1": "Wagistrasse 14", "city": "Schlieren", "zip": "8952", "country": "Switzerland", "phone": "41 44 755 77 00", "fax": "41 44 755 77 07", "website": "https://www.molecularpartners.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.", "fullTimeEmployees": 167, "companyOfficers": [{"maxAge": 1, "name": "Dr. Patrick  Amstutz Ph.D.", "age": 48, "title": "Co-Founder, CEO, Member of Management Board & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 765014, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael Tobias Stumpp Ph.D.", "age": 51, "title": "Co-Founder, Executive VP of Projects & Member of Management Board", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Hendriks", "title": "Senior VP of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Zurcher", "age": 48, "title": "COO & Member of Management Board", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Renate  Gloggner", "age": 53, "title": "Executive VP of People & Community and Member of Management Board", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Steiner Ph.D.", "title": "Senior Vice President of Research & Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Seth D. Lewis", "title": "Senior Vice President of Investor Relations, Communications & Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Pitzner", "title": "General Counsel, Compliance Officer, Senior VP Legal & Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pamela A. Trail Ph.D.", "age": 67, "title": "Strategic Consultant", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Goubier D.V.M., Ph.D.", "title": "Senior Vice President of Research & Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.29, "open": 6.41, "dayLow": 6.1586, "dayHigh": 6.48, "regularMarketPreviousClose": 6.29, "regularMarketOpen": 6.41, "regularMarketDayLow": 6.1586, "regularMarketDayHigh": 6.48, "beta": 0.652, "forwardPE": -3.962733, "volume": 2235, "regularMarketVolume": 2235, "averageVolume": 39017, "averageVolume10days": 19250, "averageDailyVolume10Day": 19250, "marketCap": 218570512, "fiftyTwoWeekLow": 3.32, "fiftyTwoWeekHigh": 12.7, "priceToSalesTrailing12Months": 32.49636, "fiftyDayAverage": 6.52292, "twoHundredDayAverage": 4.775095, "currency": "USD", "enterpriseValue": 38921588, "floatShares": 17157238, "sharesOutstanding": 33182100, "sharesShort": 69861, "sharesShortPriorMonth": 86309, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0021, "heldPercentInstitutions": 0.028800001, "shortRatio": 1.51, "impliedSharesOutstanding": 34258700, "bookValue": 5.128, "priceToBook": 1.2441498, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -58531000, "trailingEps": -2.06, "forwardEps": -1.61, "enterpriseToRevenue": 5.787, "enterpriseToEbitda": -0.639, "52WeekChange": 0.06333339, "SandP52WeekChange": 0.24822903, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MOLN", "underlyingSymbol": "MOLN", "shortName": "Molecular Partners AG", "longName": "Molecular Partners AG", "firstTradeDateEpochUtc": 1623850200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3b1227e2-09aa-3330-8282-b0e2c7493dad", "messageBoardId": "finmb_32677064", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.38, "targetHighPrice": 16.93, "targetLowPrice": 4.08, "targetMeanPrice": 8.99, "targetMedianPrice": 5.97, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 174132992, "totalCashPerShare": 5.298, "ebitda": -60955000, "totalDebt": 3351000, "quickRatio": 14.441, "currentRatio": 14.676, "totalRevenue": 6726000, "debtToEquity": 1.988, "revenuePerShare": 0.205, "returnOnAssets": -0.17982, "returnOnEquity": -0.29962, "freeCashflow": -36798752, "operatingCashflow": -59510000, "revenueGrowth": -0.102, "operatingMargins": -5.79182, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]